Janux raises $56M to take safer T-cell engagers into the clinic ntaylor Wed, 03/03/2021 - 03:06.: Janux Therapeutics has raised $56 million to fund development of T-cell engagers (TCEs). The series A will fund preclinical work on TROP-2 and PSMA candidates, positioning Janux to enter the clinic next year. Driven by work at companies including Amgen, TCEs have emerged as a promising cancer modality. Yet, in the view of Janux CEO David Campbell, Ph.D., existing platforms suffer from shortcomings that limit the utility of TCEs.